Amerigen announced that the Food and Drug Administration (FDA) has granted final approval to the Abbreviated New Drug Application (ANDA) for Temozolomide Capsules, the generic version of Merck’s Temodar.

Temodar is an alkylating agent indicated for the treatment of newly diagnosed glioblastoma multiforme and for refractory anaplastic astrocytoma. It exerts its cytotoxic activity by undergoing nonezymatic conversion to a reactive compound, which alkylates DNA through methylation. 

Related Articles

Temozolomide Capsules are available in 5mg, 20mg, 100mg, 140mg, 180mg and 250mg strengths.

For more information call (732) 993-9827 or visit